FEBRUARY 23, 2021
A recent Eli Lilly Clinical Trial for a new Type 2 Diabetes drug showed that the molecule has a dramatic effect in patients, lowering their A1C and weight. In this global study (the number of patients is 1,875 over 65 sites), South Florida Clinical Research Institute (SFCRI) provided its quota of patients and data to the success of Lilly’s diabetes molecule. This success transcends into our business group, as SFCRI’s LeRoy Reynolds worked with Leverage Business Strategy (Gil Sternbach) on its CTA (Clinical Trial Agreement) to facilitate negotiations with Eli Lilly & company.
You can read more about the study here.
Wed, September 30 2020